Search This Blog

Thursday, July 2, 2026

Nuclear Reactor Powers Nvidia AI Chip in US First

 alar Atomics Inc., a California-based nuclear startup, generated power from an advanced reactor to run an Nvidia Corp. AI chip. While just a trickle of electricity was produced, it's the first time a next-gen reactor has done so in the US.

Valar's Ward 250 reactor was connected to the Nvidia Blackwell chip during a demonstration Wednesday at the company's site in Utah, and used to temporarily host a website. The two companies also announced an agreement to jointly explore ways to develop nuclear-powered AI systems.

The latest step follows the reactor reaching "criticality" last month, marking the start of a self-sustaining fission reaction. Valar is part of a wave of companies developing next-generation nuclear technologies that use new materials and designs intended to improve safety and performance. However, the industry is still in its early stages, and no US advanced reactors are commercially available.

https://finance.yahoo.com/technology/ai/articles/nuclear-firm-first-us-produce-211439173.html

Google: Action taken against NetNut's malicious network

 Google LLC announced in a blog post on Thursday that, in coordination with the FBI, Lumen, and others, it took action against the NetNut residential proxy network, also known as Popa.

To disrupt the proxy network, Google accounts and associated Google services used by NetNut for malware command and control (C2) were disabled, technical intelligence on NetNut software development kits (SDKs) and backend C2 infrastructure was shared, and Google's Play Protection "automatically warned users and disabled applications known to incorporate NetNut SDKs."

The tech giant stated that the coordinated actions significantly degraded the proxy network, "reducing the available pool of devices for the proxy operator by millions." Google Threat Intelligence Group (GTIG) estimated that NetNut's network size is at least 2 million devices.

https://breakingthenews.net/Article/Google:-Action-taken-against-NetNut's-malicious-network/66625044

Colorado's pathfinder medicine price-cap move stalls

 A federal judge in the US has sided with Amgen in a dispute over a price cap imposed by the state of Colorado on its blockbuster immunology drug Enbrel.

In a move viewed as a test of states' ability to impose drug pricing controls, the Colorado Prescription Drug Affordability Review Board (PDAB) placed a $600-per-week price cap on the drug last October for a standard weekly dose – about $31,000 per year – but almost 50% lower than typical prices in the state in 2023.

The first-of-its-kind price cap has been overturned by Judge Daniel Domenico in the Denver federal court, who accepted Amgen's request to impose a preliminary injunction on the cap – known as an upper payment limit – on the grounds that it is pre-empted by federal law and violates due process and commercial rights.

In its lawsuit, Amgen claimed the upper payment limit for Enbrel (etanercept), a widely used TNF inhibitor for diseases like rheumatoid arthritis, would cause it to "suffer substantial, irreparable harm."

The company made almost $2 billion from the brand last year in the US, out of global sales of $2.23 billion, although, sales have been falling steadily from a peak of more than $8.5 billion in recent years since the start of biosimilar competition overseas. In the US, biosimilars have been approved, but are blocked from launch by ongoing patent litigation and are not expected to reach the market until 2029.

"Both parties make important, and persuasive, policy arguments," wrote Domenico in his ruling on the case.

"Colorado is undoubtedly correct that the price of many beneficial medications is difficult, if not impossible, for many citizens to afford," he added. "Amgen is correct that the development of the new medications many of us benefit from requires that profits from the few successful ones be large enough to cover not only their own development, but that of dozens of failed experiments."

He pointed out, however, that these "policy issues" are not relevant to the case under consideration, as "under binding Federal Circuit precedent, caps on the price of patented drugs like Enbrel are preempted by federal law."

The PDAB had contended that Amgen would not be harmed by the cap because of the convoluted way Enbrel is paid for at various levels of the supply chain, which is typical of the US market and makes it hard to tease out accurate pricing data.

Domenico wrote that drug pricing is remarkable for its "puzzling opacity," but added that it is "not necessary to unravel the entire system to understand that, as a result of Colorado's cap, Amgen will receive less money from its wholesalers and will fare more poorly in negotiations with other purchasers in Colorado and elsewhere."

He advised the PDAB to try to reduce Enbrel's price through subsidies or negotiations to lower prices, as has been done by the federal government through the Medicare system.

The preliminary injunction pauses the cap, which had been due to come into effect at the start of next year, while the underlying lawsuit proceeds.

https://pharmaphorum.com/news/colorados-pathfinder-medicine-price-cap-move-stalls

Almost half of dementia cases could be prevented, says study

 A study has found that nearly half of all cases of dementia are avoidable with lifestyle changes, but public health campaigns have proven to be ineffective at driving change.

The review of a dozen national, population-level awareness campaigns targeting modifiable risk factors like physical inactivity, smoking, low education, and social isolation – published in The Lancet Healthy Longevity journal – has found they have broad reach, but deliver only marginal benefits.

The researchers behind the work, from Curtin University in Australia, say that more engaging, personalised, and community-driven approaches are needed to genuinely influence behaviour and reduce dementia risk.

The results of the analysis reveal "a clear gap between what people know and what they do," according to the researchers, led by Professor Mario Siervo from Curtin's School of Population Health.

"Up to 45% of dementia cases are linked to modifiable factors we can change, such as our lifestyle, health status, and environment," he said. "But simply telling people what those risks are isn't enough; awareness campaigns are important, but on their own they rarely lead to meaningful or lasting behaviour change."

Interventions requiring active engagement – such as online courses, e-learning programmes, and community-based approaches – produce stronger behavioural effects than passive information-only approaches.

When combined with personalised risk profiling showing individuals how their lifestyle affects their dementia risk, the approach could deliver a 26% improvement in modifiable risk factor status over three years, they suggest.

Body composition study

In a separate study, published in the journal Clinical Nutrition, Siervo and colleagues explored other modifiable risk factors for dementia, specifically muscle strength and body composition.

They followed nearly 500,000 adults with sarcopenic obesity - defined as the combination of excess body fat and low muscle mass and strength - for more than a decade, and found a 30% increased risk of dementia, while obesity on its own was not associated with increased dementia risk if muscle strength was preserved.

Study co-author Prof Blossom Stephen, chair in dementia at Curtin's enAble Institute, said the results provide further evidence that dementia risk is modifiable, and not an unavoidable part of ageing.

However, "even when people are aware of the risks, barriers such as time, cost, and motivation can prevent them from making changes to their lifestyle," she added.

"We need to combine broad public messaging with targeted support that helps people take action. That means investing in programmes that are accessible, culturally relevant, and designed with communities, not just delivered to them."

https://pharmaphorum.com/news/almost-half-dementia-cases-could-be-prevented-says-study

Walz Pardons Convicted Child-Molester, Blocking Deportation

 A Minnesota pardon board that includes Gov Tim Walz among its three members has issued a full pardon to a convicted Laotian child-molester, torpedoing Homeland Security's effort to deport him. The 42-year-old convict, Tou Lue Vang, submitted a letter to the board saying he regretted what he did -- and just like that, his criminal record is now clean as a whistle via unanimous decision. 

“Governor Tim Walz's decision to pardon an illegal alien convicted child rapist so he can remain in our country is disgusting,” said DHS spokeswoman Lauren Bis. “These are the criminal illegal aliens he and his Minnesota sanctuary politicians are protecting. Tou Lue Vang lost his legal status following his conviction for repeatedly sexually assaulting a 10-year-old girl." 

Tou Lue Vang told the pardons board that he had regrets about abusing a 10-year-old girl multiple times (DHS photo)

In a storyline that has Democrats co-conspiring to infuse precious "diversity" into the American bloodstream over more than three decades, the Clinton administration granted Vang legal status after he entered the United States as a child in 1994. Now, 2024 Democratic vice presidential nominee Tim Walz has  helped guarantee that the convicted sex fiend will be safe from deportation. The two other members of the pardon board are Minnesota Attorney General Keith Ellison and chief Supreme Court justice, Natalie Hudson

Vang was convicted of sexually assaulting a girl who was just 10 years old when his perverted acts began. He repeated the offense with the same girl between 2002 and 2004, and pathetically tried to buy her silence with an offer of just $10 in hush money.  After his conviction, an immigration judge ordered his removal way back in 2006.  

When he was first interrogated by police, Vang tried to sweep away the gravity of his actions, telling them, "it is a cultural thing...to marry and have sex with girls as young as 12.” Apparently, Walz -- who's heralded as a reliable "ally" for the LGBTQ crowd and famously put tampons in school-kids' boys rooms -- thinks diversity in sexual morality is our strength too. Vang's pardon quest was bolstered by a supportive letter to the board from his victim, along with many letters of support from the "community."  

Minnesota Gov Tim Walz was part of a unanimous decision that will prevent a child-molester's deportation

Minnesota is on a roll when it comes to helping Laotian criminals stay in America. "In May, the state pardoned Jai Vang, a criminal illegal alien from Laos, whose criminal record includes convictions for robbery, robbery of a business with a gun, and driving under the influence of liquor," noted DHS in a statement. He was ordered to be removed from the United States -- you better sit down for this --  in May 1996. The Clinton administration sprung him loose. Between March 2025 and June 2026, Minnesota has received 67 pardon requests that cite immigration woes as a reason for seeking forgiveness. Across all decisions made this year, the Minnesota board has approved an overwhelming 94% of pardons requested. 

Of course, the Trump administration is in a glass house when it comes to throwing rocks about pardons. Among too many other examples, Trump has stirred the disgust of victims and law-and-order Republicans alike with pardons or commutations of: 

  • Joseph Schwartz, a nursing home operator in New York convicted of a $39 million tax fraud scheme
  • Eliyahu Weinstein, a real estate developer who'd been convicted of a real estate Ponzi scheme; after his 24-year sentence was commuted after only a few months, he immediately started orchestrating a scheme in which he defrauded people who thought they were investing in deals to get scarce medical supplies to war-torn Ukraine
  • Sholam Weiss, who was staring down an 845-year sentence for racketeering, wire fraud, money laundering, and transporting stolen goods, after defrauding an insurer and its elderly policyholders out of £91 million; he fled the US before he could be prosecuted and was convicted in absentia
https://www.zerohedge.com/political/minnesota-gov-walz-pardons-convicted-child-molester-blocking-deportation

FDA Staffers Oppose Proposed Clearance Of Peptides

 by Zachary Stieber via The Epoch Times,

Food and Drug Administration staffers said in newly released documents that they do not support letting compound pharmacies manufacture seven popular peptides.

FDA personnel said in documents posted online on June 29 that there are safety concerns with the peptides, including the possibility of triggering immune responses that could lead to "life-threatening and catastrophic reactions."

They do not favor classifying BPC-157, KPV, TB-500, MOTS-c, Emideltide, Epitalon, or Semax in a way that would let pharmacies use them in compounded medicines.

Peptides are short chains of amino acids that act as building blocks of proteins and perform essential biological functions in the body. If permitted, compounding pharmacies can manufacture them for personalized medications tailored to patients' unique needs.

They have become popular among some fitness influencers and have received endorsement from Health Secretary Robert F. Kennedy Jr.

Compounding refers to doctors and pharmacists creating customized medicine by combining, mixing, or altering ingredients.

The documents were posed ahead of a scheduled meeting of the FDA's Pharmacy Compounding Advisory Committee, which will consider whether to support or oppose loosening restrictions on the peptides.

The FDA in April said it would not take action against compounding pharmacies that use some of the peptides, and is now considering whether to add them to a list of approved substances.

The FDA could create some guard rails within which peptides could be prepared by legitimate pharmacies, according to Scott Brunner, CEO of Alliance for Pharmacy Compounding, a trade association for pharmacies.

"We would urge the agency to look at this not as an up or down vote, but to consider a middle path that does address a very real public health concern," Brunner said.

Ban

The FDA in 2023 labeled more than a dozen peptides, including BPC-157 and KPC, as substances banned for compounding.

Officials at the time said there was a lack of information on the peptides. The available data indicated "significant safety risks," they said.

Kennedy has said the ban was illegal. Such bans should only happen if there is a safety signal, he has said.

No such safety signal was identified.

Rep. Diana Harshbarger (R-Tenn.), a pharmacist, wrote to officials in 2025 in support of allowing the compounding of six peptides, including BPC-157.

New Members

The FDA appointed multiple new members to the compounding panel, including seven who have links to businesses or clinics involved in peptide therapies.

That includes Robert Harshbarger, a Tennessee senator, pharmacist, and son of Rep. Harshbarger.

"All committee members underwent the same ethics review and vetting process required of all FDA advisory committee members," a Department of Health and Human Services spokesperson said.

"Candidates that could not meet existing ethics requirements were removed from consideration."

https://www.zerohedge.com/medical/fda-staffers-oppose-proposed-clearance-peptides

'KFF: These Women Had Their Breasts Removed to Thwart Cancer. Then Came the Pain'

 Three weeks after Sophia Bassan's mastectomy, she felt a stabbing pain beneath her right armpit. In the following months, painful shocks radiated through her chest and back. Her body became so sensitive that at times she couldn't wear a shirt or lift a fork to her mouth.

Bassan slept sitting up because it hurt to lie down, and she would flinch at the slightest touch.

"I remember thinking I was losing my mind," said Bassan, 43. "One time I was in so much pain that I had to take off my top, and then my cat's tail brushed against my back. I screamed."

Mastectomies are lifesaving surgeries that remove a patient's breasts to treat breast cancer, which affects 1 in 8 American women over their lifetimes, according to the American Cancer Society. Some women also undergo mastectomies as a preventive measure after a genetic test shows they have an increased risk for breast cancer.

In the months following surgery, many women are afflicted by post-mastectomy pain syndrome, or PMPS, which spans from uncomfortable to disabling and can last years.

Yet PMPS is inconsistently diagnosed and treated, leaving women like Bassan in agony as they hunt for relief and struggle to find doctors who take their pain seriously, according to a KFF Health News review of peer-reviewed research studies and interviews with pain specialists, surgeons, patients, and patient advocates.

Another problem is that PMPS is poorly defined, which contributes to the wide range of estimates for how common it is, reaching as high as more than 50% of mastectomy patients, according to studies. Even the low-end estimates, around 10%, would amount to tens of thousands of women.

PMPS care could improve if lawmakers pass the Advancing Women's Health Coverage Act, which was introduced in October to ensure insurance coverage after breast cancer treatment, including preventive mastectomies. The bill, which does not mention PMPS by name, covers complications including chronic pain. More research would help, but pain research has long been fractured across several medical specialties and, more recently, has been undermined by the administration of President Donald Trump, who last year proposed deep cuts to research funding at the NIH. After Congress rejected those cuts earlier this year, the White House slowed the release of NIH grant money, hindering ongoing and future scientific research.

"I've known women who've had chronic pain -- itching, burning, stabbing pain -- for years after mastectomies," said Kathy Steligo, an author of multiple books on breast cancer who said she has spoken with hundreds of patients. "Of all the problems, that is probably the one least talked about by surgeons."

Four mastectomy patients interviewed by KFF Health News told similar stories. In separate interviews, patients said their presurgery consultations did not raise the possibility of post-mastectomy pain syndrome, although each said they had signed forms that may have disclosed the chance of this complication. All said that they felt blindsided by the chronic pain, and some said their doctors dismissed their symptoms.

"Women don't know about this, and when they have complications, the doctors act like it is so rare, like they're so baffled," Bassan said. "But this is statistically predictable."

Jennifer Drubin Clark, 42, struggled with pain after her mastectomy in 2018, and it worsened after reconstructive breast surgery in 2019.

But her surgeon seemed to focus only on the appearance of her breast implants, she said.

"I couldn't play the piano. I wanted to blow-dry my hair, but I couldn't hold my arm above my head for more than 2 seconds. I couldn't hold my kids," Clark said. "Everything made me cry."

Pain Often Dismissed

Breast cancer survival rates have steadily increased since the 1980s thanks to improved cancer screening, genetic testing, better treatments, and a rise in mastectomy surgeries.

Post-mastectomy pain syndrome is a consequence of that success, according to recent research papers from anesthesiologists at Baylor University in Texas and surgeons in Chicago and New York. Both papers called for an increased focus on PMPS so that breast cancer patients can not only live longer but live well.

"In the past, when concern was predominantly on patient survival, this pain was often considered acceptable," plastic surgeons Jonathan Bank, MD, and Maureen Beederman, MD, wrote in a 2021 paper, adding that mastectomies and other breast surgeries "should be considered truly successful only if patients are pain-free."

Treatment for post-mastectomy pain has a long way to go, said anesthesiologist Sean Mackey, MD, PhD, who leads the pain medicine division at Stanford University. Mackey said this "undertreated" condition has no consistent definition for diagnosis, no standardized screening, and no treatment approved by the FDA.

Even the name is a misnomer, Mackey said, since the same pain can arise among women who've had other procedures, including lumpectomies and lymph node surgeries.

"The condition was historically dismissed," Mackey said. "Basically women were told: 'You're lucky to be alive. Some pain is expected. Suck it up and deal with it.'"

"That attitude has been slow to change," he said.

Bank, a New York surgeon who founded a clinic focused on post-mastectomy pain, said the pain is believed to be triggered by nerves that are severed during surgery and then left that way.

The nerves can be sutured back together to minimize pain, Bank said, but most breast surgeons haven't been trained to do this. So it is not surprising, he said, that some patients say their surgeons were dismissive of their pain after mastectomies.

"When doctors don't have an answer or don't know the solution, the easiest thing to do is say there is no problem," Bank said.

PMPS has been documented among cancer patients since the 1970s. Although the condition does not have an official definition, many researchers describe it as frequent pain in the chest, shoulder, arm, or armpit lasting at least 3 months after surgery.

Mastectomies intended to prevent breast cancer have become more common among women with elevated risks, including genetic mutations and a family history of the disease.

Bassan's grandmother died of breast cancer when she was 40. After her father died of cancer in 2023, a genetic test showed that she was at risk. Grieving and afraid, Bassan sought a preventive mastectomy without hesitation, she said.

Bassan said she was also inspired by actor Angelina Jolie, who disclosed her own preventive mastectomy in a 2013 column in the New York Times. Her account had such a significant impact on rates of genetic testing and preventive mastectomies that medical researchers have studied what they call the "Angelina Jolie effect."

"I was really swayed by that," Bassan said. "She made it sound, in a way, quite effortless."

The aftermath of Bassan's surgery was far worse than she expected. Using a computer for hours triggered paralyzing pain, so she lost her job and has been out of work for more than a year. Prescription pills dulled the pain but left her in a fog, she said. Desperate, she consulted with multiple doctors until one suggested a nerve stimulation machine, which provided fleeting relief.

About 9 months after her mastectomy, a breast reconstruction surgery lessened Bassan's pain, although she said it still returns in occasional waves. Even though her surgeries were covered by insurance, Bassan estimated her pain has cost her more than $200,000 in lost wages and drained savings.

"I did not expect to pay this price to have this surgery," Bassan said. "I don't know if it was worth it."

Other women have no real choice.

No 'Gold Standard' Solution

Jeni Golomb, 48, was diagnosed with stage II cancer in both breasts in 2023 and had a double mastectomy as soon as she could.

Doctors made boilerplate disclosures of possible complications, Golomb said, but she never heard the words "post-mastectomy pain syndrome" until after she had it.

Golomb now manages her chronic pain by taking 1,500 mg a day of gabapentin, an anti-seizure drug that can also be used to treat nerve pain. Golomb said she expects to take the drug for years. If she misses a dose, her pain comes roaring back.

"It was the worst pain I ever felt," Golomb said. "I labored to 10 cm, unmedicated, with one of my children, and that was not as bad as this. It was excruciating."

Gabapentin has proved effective at helping some mastectomy patients with stubborn pain, while others have responded to electrodes implanted in their spinal column, according to the Baylor study, published in 2024.

But that study also said there is "no current gold standard" for how to treat post-mastectomy pain and a scarcity of high-level evidence for what treatments are effective.

Baylor anesthesiologist Krishna Shah, MD, who co-authored the report, said many patients eventually find a helpful treatment, but it often takes "a bit of trial and error" to identify what works for each.

And sometimes they never find it.

Susan Dishell, 67, said that after her 2017 mastectomy for breast cancer and reconstruction surgery, she struggled for 5 years with pain in both shoulders, plus a burning sensation that her medical records identified as nerve pain.

Another surgery swapped out her breast implants to erase her shoulder pain in 2022, Dishell said, but doctors warned her then that her other pain was unlikely to improve.

Since then, she has tried prescription drugs, steroid injections, CBD oil, acupuncture, physical therapy, and chiropractor treatments.

None of it worked, she said, so she stopped trying.

"I have not slept through the night since I've had this," Dishell said. "But it's OK. It's not the most terrible price to pay to not have breast cancer."

https://www.medpagetoday.com/hematologyoncology/breastcancer/120658